Post-exposure prophylaxis for rabies

Journal, Indian Academy of Clinical Medicine

Volumn 7, Issue 1, 2006, Pages 39-46

  Shayam, C ^a   Duggal, A K ^a   Kamble, Ulka ^a   Agarwal, A K ^a  

^a DR RAM MANOHAR LOHIA HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ABHAYRAB; CORTICOSTEROID; IMMUNOGLOBULIN; RABIES VACCINE;

BITE; DIZZINESS; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; LYMPHADENOPATHY; MALAISE; MYALGIA; PARALYSIS; PROPHYLAXIS; PRURITUS; RABIES; REVIEW;

EID: 33644879156     PISSN: 09723560     EISSN: 09723560     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. WHO: the world health report, Geneva. World Health Organisation 1996; 57.
2. WHO: the health situation in South-East Asia Region. New Delhi Regional office of SEAR 1994-7.
3. King AA, Meredith CD, Thomson GR. The biology of southern African lyssavirus variants. Curr Top Microbiol Immunol 1994; 187: 267-95.
4. Rupprecht CE, Gibbons RV. Prophylaxis against Rabies. N Engl J Med 2004; 351 (25): 2626-35.
5. Willoughby RE Jr, Tieves KS, Hoffman GM et al. Brief report: Survival after treatment of rabies with induction of coma. N Engl J Med 2005; 352: 2508-14.
6. Meslin FX, Kaplan MM., Koprowski H. Laboratory techniques in rabies; 4th edition; World Health Organization, Geneva, 1996.
7. Mahajan BK, Gupta MC. Textbook of Preventive and Social Medicine 2nd ed. Delhi. Jaypee Brothers, 1995; 351.
8. Park K. Park's Textbook of Preventive and Social Medicine 17th ed. Jabalpur. M/s Banarsidaas Bhanot 2002; 207-15.
9. Briggs DJ, Dreesen DW, Wunner WH. Vaccines. In: Jackson AC, Wunner WH, eds. Rabies. San Diego, USA: Academic Press, 2002; 371-400.
10. Bahri E,Letaief A, Emez M et al. Neurological complictions in adults given post exposure Semple type rabies vaccine. Presse Med 1996; 25: 491-3.
11. Current WHO guide for Rabies Pre- and Post-exposure treatment in humans. WHO Department of Communicable Diseases Surveillance and Response. (Accessed July 29, 2005, at http://www.who.int/rabies/en/ WHO_guide_rabies_pre_post_exp_treat_humans.pdf).
12. King AA, Turner GS. Rabies: a review. J Comp Pathol 1993; 108: 1-39.
13. Wiktor TJ, Plotkin SA, Koprowski H. Development and clinical trials of the new human rabies vaccine of tissue culture (human diploid cell) origin. Dev Biol Stand 1978; 40: 3-9.
14. CDC. Rabies prevention: supplementary statement on the pre-exposure use of human diploid cell rabies vaccine by the intradermal route. MMWR 1986; 35: 767-8.
15. Bahmanyar M. Results of rabies post-exposure treatment with antirabies serum and the human diploid cell vaccine in Iran. Dev Biol Stand 1978; 40:163-5.
16. Sehgal S, Bhattacharya D, Bhardwaj M. Ten-year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 1995; 27 (1): 36-43.
17. Natrajan M, Mukandan P, John TJ. Immune response to purified chick embryo cell culture rabies vaccine manufactured in India. Indian J Med Res 1992; 95: 51-3.
18. Bijok U, Vodopija I, Smerdel S et al. Purified chick embryo cell (PCEC) rabies vaccine for human use: clinical trials. Behring Inst Mitt 1984; 76: 155-64.
19. Sampath G, Reddy SV, Rao ML et al. An immunogenicity study of a newly introduced purified Vero cell rabies vaccine (AbhayrabTm) manufactured in India. Vaccine 2005; 23 (7): 897-900.
20. Burgoyne GH, Kajiya KD, Brown DW, Mitchell JR. Rhesus diploid rabies vaccine (adsorbed): a new rabies vaccine using FRhL-2 cells. J Infect Dis 1985; 152: 204-10.
21. WHO Expert Committee on Rabies, 8th report. Geneva: World Health Organisation, 1992; TRS 824.
22. Childs JE, Colby L, Krebs JW et al. Surveillance and spatiotemporal associations of rabies in rodents and lagomorphs in the United States, 1985-1994. J Wildl Dis 1997; 33: 20-7.
23. Human rabies prevention - United States, 1999: Recommendations of the Immunisation Practices Advisory Committee (ACIP). MMWR Recomm Rep 1999; 48 (RR1): 1-21.
24. Fishbein DB, Pacer RE, Holmes DF et al. Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a doseresponse study. J Infect Dis 1987; 156: 50-5.
25. Pappaioanou M, Fishbein DB, Dreesen DW et al. Antibody response to preexposure human diploid-cell rabies vaccine given concurrently with chloroquine. N Engl J Med 1986; 314: 280-4.
26. Nicholson KG. Rabies. Lancet 1990; 335: 1201-5.
27. Quiambao BP, Dimaaano EM, Ambas C et al. Cross postexposure regimen in patients severely exposed to laboratory-confirmed rabid animals. Vaccine 2005; 23 (14): 1709-14.
28. Madhusudana SN, Anand NP, Shamsundar R. Economical multi-site intradermal regimen with purified chick embryo cell vaccine (RabipurTm) prevents rabies in people bitten by confirmed rabid animals. Int J Infect Dis 2002; 6 (3): 210-4.
29. Madhusudana SN, Anand NP, Shamsundar R. Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies. Natl Med J India 2001; 14 (3): 145-7.
30. Wang XJ, Lang J, Tao XR et al. Immunogenicity and safety of purified Vero-cell rabies vaccine in severely rabiesexposed patients in China. Southeast Asian J Trop Med Public Health 2000; 31 (2): 287-94.
31. Nicholson KG, Turner GS, Aoki FY. Immunisation with a human diploid cell strain of rabies virus vaccine: Two year results. J Infect Dis 1978; 137: 783-8.
32. Sehgal S, Bhattacharya D, Bhardwaj M. Ten-year longitudinal study of efficacy and safety of purified chick embryo cell vaccine for pre- and post-exposure prophylaxis of rabies in Indian population. J Commun Dis 1995; 27: 36-43.
33. Deshpande AK, Londhe VA, Akarte S, Briggs D. Comparative evaluation of immunogenicity, reactogenecity and safety of purified chick embryo cell rabies vaccine and neural tissue rabies vaccine. J Assoc Physicians India 2003; 51: 655-8.
34. Wilde H, Sirikawin S, Sabcharoen A et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 1996; 22 (2): 228-32.
35. Arya SC. Therapeutic failures with rabies vaccine and rabies immunoglobulin. Clin Infect Dis 1999; 29 (6): 1605.
36. Cabasso VJ, Loofbourow JC, Roby RE, Anuskiewicz W. Rabies immune globulin of human origin: preparation and dosage determination in non-exposed volunteer subjects. Bull World Health Organ 1971; 45: 303-15.
37. Helmick CG, Johnstone C, Sumner J et al. A clinical study of Merieux human rabies immune globulin. J Biol Stand 1982; 10: 357-67.
38. Tantawichien T, Benjavongkulchai M, Wilde H et al. Value of skin testing for predicting reactions to equine rabies immune globulin. Clin Infect Dis 1995; 21 (3): 660-2.
39. WHO - Report of a WHO consultation on intradermal application of human rabies vaccines; March 13-14, 1995. Geneva, World Health Organization, 1995.
40. Atkinson TP, Kaliner MA. Anaphylaxis. Med Clin N Amer 1992; 76: 841-55.
41. Cupo P, de Azevedo-Marques MM, Sarti W, Hering SE. Proposal of abolition of the skin sensitivity test before equine rabies immune globulin application. Rev Inst Med Trop Sao Paulo 2001; 43 (1): 51-3.
42. WHO - Recommendations on rabies post-exposure treatment and the correct technique of intradermal immunisation against rabies. Geneva, World Health Organization, 1997.
43. Wilde H, Chomchey P, Prakongsri S, Punyaratbandhu P. Safety of equine rabies immune globulin. Lancet 1987; 2: 1275.
44. Wilde H, Chutivongse S. Equine rabies immune globulin: a product with an undeserved poor reputation. Am J Trop Med Hyg 1990; 42 (2): 175-8.
45. Wilde H, Chomchey P, Punyaratabandhu P et al. Purified equine rabies immune globulin: a safe and affordable alternative to human rabies immune globulin. Bull World Health Organ 1989; 67 (6): 731-6.
46. Lodmell DL. Rabies DNA vaccines for protection and therapeutic treatment. Expert Opin Investig Drugs 1999; 8 (2): 115-22.